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muscle mass and function associated with aging of
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ABSTRACT: Age-related skeletal muscle dysfunction is the underlying cause of morbidity that affects up to half
the population aged 80 and over. Considerable evidence indicates that oxidative damage and mitochondrial dys-
function contribute to the sarcopenic phenotype that occurs with aging. To examine this, we administered the
mitochondria-targeted antioxidant mitoquinone mesylate {[10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-
1-yl)decyl] triphenylphosphonium; 100 mM} to wild-type C57BL/6 mice for 15 wk (from 24 to 28 mo of age) and
investigated the effects on age-related loss of muscle mass and function, changes in redox homeostasis, and mito-
chondrial organelle integrity and function. We found that mitoquinone mesylate treatment failed to prevent age-
dependent loss of skeletal muscle mass associated with myofiber atrophy or alter a variety of in situ and ex vivo
muscle function analyses, including maximum isometric tetanic force, decline in force after a tetanic fatiguing
protocol, and single-fiber-specific force.We also found evidence that long-termmitoquinonemesylate administration
did not reduce mitochondrial reactive oxygen species or induce significant changes in muscle redox homeostasis, as
assessed by changes in 4-hydroxynonenal protein adducts, protein carbonyl content, protein nitration, and DNA
damagedeterminedby the content of 8-hydroxydeoxyguanosine.Mitochondrialmembrane potential, abundance, and
respiration assessed in permeabilized myofibers were not significantly altered in response to mitoquinone mesylate
treatment. Collectively, these findings demonstrate that long-term mitochondria-targeted mitoquinone mesylate ad-
ministration failed to attenuate age-related oxidative damage in skeletal muscle of old mice or provide any protective
effect in thecontextofmuscleaging.—Sakellariou,G.K.,Pearson,T.,Lightfoot,A.P.,Nye,G.A.,Wells,N.,Giakoumaki,
I. I., Griffiths, R. D., McArdle, A., Jackson, M. J. Long-term administration of the mitochondria-targeted antioxidant
mitoquinone mesylate fails to attenuate age-related oxidative damage or rescue the loss of muscle mass and function
associated with aging of skeletal muscle. FASEB J. 30, 3771–3785 (2016). www.fasebj.org
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Age-related loss of muscle mass and function underlies
morbidity and mortality that affects up to half the pop-
ulation aged 80 yr and older (1). Loss ofmuscle strength in
the elderly is a contributor to loss of independence and to
physical disability,which is linked to increased risk of falls
and fractures. Many structural and functional changes
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occur with advancing age in skeletal muscle, including a
reduction in the number and cross-sectional area (CSA) of
individual muscle fibers (2).
Oxidative stress has been suggested to be among
the factors contributing to the initiation and progres-
sion of sarcopenia that occurs during aging (3, 4). Re-
ports from our group (5–11) and others (12, 13) have
shown that genetic manipulations of redox regulatory
systems modifies the muscle aging process. Skeletal
muscle has a high content of mitochondria (14), and
mitochondrial redox homeostasis has been proposed
to play a key role in age-related oxidative damage (15).
Consistentwith a role ofmitochondria as a contributor
to age-related muscle redox changes, studies have
shown that isolated skeletal muscle mitochondria ex-
hibit an age-dependent increase in hydrogen peroxide
(H2O2) generation (16, 17).
Reactive oxygen species (ROS) derived from mito-
chondria [mitochondrial ROS (mtROS)] are linked to
the pathogenesis of a number of age-related human
diseases, including neurodegenerative disorders, ischemia–
reperfusion injury, and diabetes (18, 19). Considerable
evidencehas shown thatmitochondrial oxidativedamage
can alter mitochondrial integrity and function in aging
skeletal muscle, including a reduction in mitochondrial
abundance (20) and oxidative phosphorylation (21), ac-
cumulation of mutated mitochondrial DNA (mtDNA)
(15) associated with impaired mitophagy (22), and in-
creased mitochondrial-mediated apoptosis (23), which
could all contribute to sarcopenia. Although cumulative
oxidative damage has been suggested to induce age-
associateddecline inmitochondrial function (24), the effects
of mitochondrial dysfunction and mtROS in age-related
muscle atrophy remains a controversial topic (25, 26).
To directly examine whether age-related atrophy and
mitochondrial dysfunction is related to mitochondrial re-
dox changes, we administered the mitochondria-targeted
antioxidant mitoquinone mesylate {[10-(4,5-dimethoxy-2-
methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl] triphenyl-
phosphonium} to 24-mo-old for 15wkand investigated the
effects on age-related loss of muscle mass and function,
changes in muscle redox homeostasis, and mitochondrial
organelle function and content. We hypothesized that if
alterations in the mitochondrial redox status are impli-
cated in the processes of age-related muscle wasting,
mitoquinone mesylate drug treatment would ameliorate
the sarcopenic phenotype associated with loss of muscle
mass and weakness. In the present study, we report
the effects of long-term administration of mitoquinone
mesylate on muscle mass, morphology, and function; re-
dox homeostasis; adaptive responses; and mitochondrial
integrity and function in aging skeletal muscle.
MATERIALS AND METHODS
Chemicals and reagents
Unless stated otherwise, all chemicals used in this study were
obtained from Sigma-Aldrich (St. Louis, MO, USA).
Mice
Male and female wild-type C57BL/6 mice (8 mo old) were
obtained from Charles River Laboratories (Margate, United
Kingdom) and aged to 28 mo at the Biomedical Services Unit,
University of Liverpool. All experiments were conducted in ac-
cordance with UK Home Office guidelines under the UK Ani-
mals (Scientific Procedures) Act 1986. Mice were fed a CRM (P)
rodent diet (Special Diet Services, Essex, United Kingdom) and
weremaintained under barrier conditions inmicroisolator cages
ona 12-hdark/light cycle. For simple tissue collection,micewere
humanely killed by cervical dislocation, andmuscles and tissues
were either rapidly removed, snap frozen, and stored at280°C,
or embedded in Tissue-Tek (VWR International, West Chester,
PA, USA) and rapidly frozen in nitrogen-chilled isopentane for
histologic analysis. Mice subjected to in situ muscle force mea-
surements were anesthetized with intraperitoneal injections of
ketamine hydrochloride (66 mg/kg) and medatomidine hydro-
chloride (0.55mg/kg), with supplemental injections provided to
maintain an adequate level of anesthesia throughout the pro-
cedure. All procedures were approved by the University of
Liverpool Animal Welfare and Ethical Review Body.
Mitoquinone mesylate administration
Mice were 24 mo of age at the start of the treatment and were
administered 100mMmitoquinonemesylate (as ab-cyclodextrin
complex; Suzhou Vosun Chemical, Jiangsu, China) in their
drinking water for the next 15 wk. Fresh mitoquinone mesylate
solutions were provided twice a week; control mice were sup-
pliedwithwater without the supplement (n = 8mice per group).
All mice were monitored daily and weighed once a week. We
selectively chose to administer mice with mitoquinone mesylate
between the ages of 24 and 28 mo because preliminary studies
showed that age-related muscle atrophy became apparent over
the timeperiodof 24 to 28mo. Thedose ofmitoquinonemesylate
used in the present study was based on that previously used
(100mM) toprotect against oxidative damage in amousemodel
of Alzheimer disease (27). Other previous studies have used
mitoquinonemesylate doses as high as 500mMfor up to 28wk (28).
In situ muscle function analysis
Extensor digitorum longus (EDL) muscle contractile properties
were measured in situ as previously described (5). To assess the
maximum isometric tetanic force (Po) of the EDLmuscle, the distal
tendonfromanesthetizedmicewasseveredandsecuredto the lever
arm of a servomotor (Aurora Scientific, Aurora, ON, Canada). The
knee of the hind limb was fixed, the peroneal nerve was exposed,
and bipolar platinumwire electrodeswere placed across the nerve.
Muscle optimal length (Lo) was determined by variation of the
length as themusclewas repeatedly stimulated at 1Hz, andmuscle
length was set where maximum force was achieved. For de-
termination of Po, EDL muscles were electrically stimulated to
contract at Lo and optimal stimulation voltage (8–10 V) at 2-min
intervals for 300 ms with 0.2-ms pulse width. Po was assessed by
increasing the frequency of stimulation from 10 to 50 Hz and sub-
sequently in 50-Hz increments to a maximum of 300 Hz. Po was
identified when the maximum force reached a plateau despite in-
creasing stimulation frequency.After identificationofPo,micewere
subjected to a repetitive tetanic fatiguing protocol, which consisted
of 60 consecutive isometric contractions (300ms at 100Hz every 5 s
for 5min) (29).After completionof theprocedures,micewerekilled
by cervical dislocation, and muscles and tissues were rapidly re-
moved. Muscle fiber length (Lf) and weight of EDL muscles were
measured ex vivo to determinemuscle CSA. SpecificPo (mN/mm
2)
was calculated by dividing Po by total fiber CSA for each muscle.
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Determination of muscle structure
Anterior tibialis (AT) muscles were cryosectioned at 220°C
through the midbelly with a thickness of 12 mm, and fluo-
rescent immunohistochemical staining was undertaken
on the same day. Sections were rinsed with PBS and
permeabilized in 0.2% Triton X-100 in PBS for 5 min.
Fluorescein-labeled wheat germ agglutinin (WGA; 5 mg/ml;
Vector Laboratories, Burlingame, CA, USA) was used to
identify extracellular matrix. Nuclei were identified using
DAPI (1 mg/ml). Cross sections from 5 to 6 muscles per treat-
ment group were examined by blinded observers to count the
total number of fibers, percentage of centronucleated fibers,
and individual fiber CSA. To ensure that all fibers per section
were analyzed, consecutive images acquired from each cryo-
section at 310 magnification were merged into a single
high-resolution image using Adobe Photoshop CS5. ImageJ
software (Image Processing and Analysis in Java; National
Institutes ofHealth, Bethesda,MD,USA)wasused to quantify
individual fiber CSA.
Confocal laser scanning microscopy
Fluorescence images were obtained using a C1 confocal laser
scanning microscope (Nikon, Tokyo, Japan) equipped with a
405-nm excitation diode laser, a 488-nm excitation argon laser,
and a 543-nm excitation helium–neon laser. Emission fluores-
cencewasdetected through a set of 450/35, 515/30, and605/15
emission filters. Fluorescence images were analyzed by Nikon
EZ-C1 3.9 (12 bit) acquisition software.
Preparation of permeabilized muscle fiber bundles
Selective plasmamembrane permeabilization of fiber bundles
was performed according tomethods described byKuznetsov
et al. (30) to allow analysis of intact skeletal muscle mito-
chondria in situ (19, 31). In brief, AT muscles were placed
in ice-cold buffer A containing (mM) 50 K-MES, 7.23 K2EGTA,
2.77 CaK2EGTA, 20 imidazole, 0.5 DTT, 20 taurine, 5.3
Na2ATP, 15 PCr, and 6.56 MgCl2 · 6H2O (pH 7.3 at 4°C) and
trimmed of connective tissue and fat. Muscles were manually
teased into small bundles of fibers and treated with 50 mg/ml
saponin (in buffer A) for 30 min at low rocking speed. After
permeabilization, fiber bundles prepared for mitochondrial
H2O2 emission measurements were washed 3 3 10 min
in ice-cold buffer Z containing (mM) 110 K-MES, 35 KCl,
1 EGTA, 5.3 Na2ATP, 10 K2HPO4, and 3MgCl2 · 6H2O (pH 7.3
at 4°C), supplemented with 5 mg/ml bovine serum albumin.
Permeabilized fiber bundles prepared for respiration analyses
were washed 33 10 min in ice-cold buffer B containing (mM)
100 K-MES, 7.23 K2EGTA, 2.77 CaK2EGTA, 20 imidazole,
0.5 DTT, 20 taurine, 3 K2HPO4, and 1.38 MgCl2 · 6H2O (pH
7.3 at 4°C) supplemented with 2 mg/ml bovine serum
albumin.
Ex vivo single muscle fiber analysis
Isolated intact single muscle fibers were excised from the AT
muscle and maintained in ice-cold relax solution containing
(mM) 4.5 MgATP, 1 free Mg2+, 10 imidazole, 2 EGTA, and
100 KCl (pH 7.0) (32). Single fibers were permeabilized with
50 mg/ml saponin (in relax solution) for 15 min on ice. Per-
meabilized fibers were mounted on an 802D muscle testing
apparatus (Aurora Scientific), mounted on insect pins with
fine thread, and attached to a 403A (5-mN) force transducer
and 312C length controller. Single fibers were maximally
activated (pCa 4.5) (2log[free Ca2+]) containing (mM) 5.3
MgATP, 1 free Mg2+, 20 imidazole, 7 EGTA, 19.6 PCr, and 64
KCl (pH 7.0). Maximal force was recorded for each fiber and
normalized to CSA (32). Sarcomere length for each individual
myofiber was adjusted to 2.4 to 2.6 mm; the diameter was mea-
sured at 4 intervals along the length of the fiber, and circular
circumference was assumed for the calculation of CSA.
Mitochondrial respiration analysis
Permeabilized myofiber respiration was assessed using
a Clark-type electrode in a continuously stirred sealed and
thermostatically controlled chamber (Oxytherm System;
Hansatech Instruments, King’s Lynn, United Kingdom)
maintained at 37°C. After calibration of the respiration
chamber, permeabilized bundles (;15 mg wet weight) were
incubated in respiration buffer B (22, 31). Respiration (O2
consumption) was determined using glutamate (5 mM) and
malate (5 mM) substrates. ADP-stimulated respiration (state
3) was initiated by addition of ADP (0.3 mM). Respiratory
control index (RCI) was calculated by dividing state 3 by
state 4 respiration, and the efficiency of oxidative phos-
phorylation was determined by calculating the ratio of ATP
amount to consumed O2 during state 3 respiration (P:O
ratio).
Mitochondrial H2O2 emission measurements
Mitochondrial H2O2 effluxwasmeasured using the Amplex
Red–horseradish peroxidase (Molecular Probes, Eugene,
OR, USA) assay as previously described (16). H2O2 pro-
duction was expressed as picomoles per minute per unit of
citrate synthase (CS) activity.
mtDNA quantification
mtDNA was measured by real-time quantitative RT-PCR (qRT-
PCR) as described by Chen et al. (33).
DNA damage and DNA fragmentation
DNA damage was assessed by the content of 8-hydroxyde-
oxyguanosine (8-OHdG) as described by Changou et al. (34).
Apoptotic DNA fragmentation was assessed by DNA laddering
usingagarosegel electrophoresis asdescribedbyHouot et al. (35).
Fluorescence-based methods to measure
mitochondrial membrane potential and MitoSOX
Red oxidation
To monitor changes in mitochondrial superoxide, isolated
permeabilized fibers from the AT muscle were loaded with
MitoSOX Red (250 nM, Thermo Fisher Scientific, Waltham,
MA, USA) for 30 min as previously described (36). Fibers
weremaintained in Z buffer containingMitoSox Red (20 nM)
during the experimental period. The reaction between super-
oxide and MitoSox Red generates a specific red fluorescent
product, 2-hydroxyethidium (2-OH-Mito-E+) (37), monitored at
an excitation/emission wavelength of 405/605 nm. Measure-
ment of mitochondrial membrane potential (DCm) in intact
mitochondria of isolated AT fibers was assessed by tetrame-
thylrhodamine, methyl ester (TMRM, 30 nM; Thermo Fisher
Scientific) fluorescence at an excitation/emission wave-
length of 543/605 nm. Changes in DCm were determined in
the presence of the oxidative phosphorylation inhibitors
oligomycin (2.5 mM) and protonophore carbonylcyanide-p-
trifluoromethoxyphenyl hydrazone (FCCP; 4 mM).
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Enzymatic activity assays
Enzymatic activity of CuZnSOD andMnSODwas assessed in
native gels, with negative staining, as described previously (6,
8). Aconitase activity was quantified by measuring the re-
duction of NADP+ to NADPH after addition of 2 U of iso-
citrate dehydrogenase by using a microplate fluorometer
(FluoStar Optima, BMGLabtech; Thermo Fisher Scientific) at
an excitation/emission wavelength of 360/460 nm (38).
Mitochondrial enzyme CS activity was determined spectro-
photometrically using the MitoCheck Citrate Synthase Ac-
tivity Assay (Cayman Chemicals, Ann Arbor, MI, USA)
according to manufacturer’s protocol. Respiratory chain
complex I activity in skeletal muscle homogenates was ex-
amined by the reduction of 2,6-dichloroindophenol, followed
spectrophotometrically at 600 nm as described by Janssen
et al. (39).
Real-time qRT-PCR analysis
RNA from skeletal muscle was extracted, DNase treated, and
purifiedusingDirect-zol RNAminiprep (ZymoResearch, Irvine,
CA, USA). Purified RNA was utilized to generate first-strand
cDNA using the iScript cDNA Synthesis kit (Bio-Rad, Hercules,
CA,USA). Primers for real-time qRT-PCR analyses are shown in
Table 1; and the optimal annealing temperature for each primer
set was determined by using an annealing temperature gradient
between 55 and 62°C. Real-time PCR reactions were performed
on an iCycler Detection System (Bio-Rad) using iQ SYBR Green
Supermix (Bio-Rad). Specificity of the PCR products was de-
termined bymelt curve analysis and agarose gel electrophoresis.
Three reference genes—glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), b-2 microglobulin (B2M), and ribosomal pro-
tein S29 (RPS29)—were used as internal controls.
Immunoblotting
Protein extracts (20 mg per sample) were separated using a
standard protocol for Western blot analysis (7). Peroxidase
activity was detected using an ECL kit (Amersham Pharmacia
Biotech, Piscataway, NJ, USA), and band intensities were an-
alyzed using Quantity One software (Bio-Rad). Mitochondrial
and cytosolic subcellular fractions were obtained from skeletal
muscle as previously described (40).
Statistical analyses
Data are presented as means 6 SEM for each experiment.
Statistical analyses for potential differences between
groups were determined by ANOVA followed by the post
hoc least significant difference test. Single comparisons be-
tween 2 experimental conditions were undertaken by the
unpaired Student’s t test. Data were analyzed by SPSS 22
(IBM SPSS, Chicago, IL, USA), and values of P , 0.05 were
considered statistically significant.
RESULTS
Age-related loss of muscle mass is associated
with myofiber atrophy
To determine the time course of age-related phenotypic
changes that occur in skeletalmuscle, we initially assessed
ATmusclemass at 12, 18, 24, and28moof age inmice (Fig.
1A). AT muscle showed age-related loss of muscle mass
[;34% reduction inmass relative to bodyweight (BM)] at
28moof age (Fig. 1A). Tounderstand the structuralmuscle
changes underlying sarcopenia, immunohistochemical
analysis ofATmuscle (Fig. 1B)wasundertaken for 18- and
28-mo-oldmice. The total number of fibers per ATmuscle
tended to be reduced by a mean of ;11% in 28-mo-old
mice compared to 18-mo-old mice (Fig. 1C), but the
changes were not significantly different. We then exam-
ined whether AT muscle of 28-mo-old mice showed atro-
phy of the remaining muscle fibers (Fig. 1D). Average
TABLE 1. Sequences of speciﬁc primers used for real-time qRT-PCR ampliﬁcation
Name
Primer sequence, 59–39
Amplicon size (bp)Forward Reverse
GAPDH CCGTAGACAAAATGGTGAAGG TCGTTGATGGCAACAATCTC 109
B2M GGAGAATGGGAAGCCGAACA TCTCGATCCCAGTAGACGGT 249
RPS29 ATGGGTCACCAGCAGCTCTA GTATTTGCGGATCAGACCGT 102
COX I CACTAATAATCGGAGCCCCA TTCATCCTGTTCCTGCTCCT 129
COX IV TGGGAGTGTTGTGAAGAGTGA GCAGTGAAGCCGATGAAGAAC 273
CS CAAGATTGTGCCCAATATCCTC TTCATCTCCGTCATGCCATA 111
MCIP1 CAGCGAAAGTGAGACCAGGG ACGGGGGTGGCATCTTCTAC 309
TFAM GCTGATGGGTATGGAGAAG GAGCCGAATCATCCTTTGC 161
PGC-1a TTCCACCAAGAGCAAGTAT CGCTGTCCCATGAGGTATT 131
NRF1 TTACTCTGCTGTGGCTGATGG CCTCTGATGCTTGCGTCGTCT 92
OPA1 TCAGCAAAGCTTACATGCAGA TGCTTGGACTGGCTACATTTT 180
MFN1 TGCCCTCTTGAGAGATGACC AGAGCCGCTCATTCACCTTA 182
MFN2 GGGGCCTACATCCAAGAGAG CCTTGGACAGGTACCCTTTG 115
FIS1 GCCTGGTTCGAAGCAAATAC CACGGCCAGGTAGAAGACAT 116
DRP1 CTGACGCTTGTGGATTTACC CCCTTCCCATCAATACATCC 277
ND1 CCTATCACCCTTGCCATCAT GAGGCTGTTGCTTGTGTGAC 194
PECAM 1 ATGGAAAGCCTGCCATCATG TCCTTGTTGTTCAGCATCAC 235
COX I, cytochrome c oxidase subunit I; COX IV, cytochrome c oxidase subunit IV; DRP1, dynamin-
related protein 1; FIS1, mitochondrial ﬁssion 1 protein; MCIP1, modulatory calcineurin interacting protein
1; MFN1, mitofusin 1; MFN2, mitofusin 2; ND1, mitochondrial encoded NADH dehydrogenase 1; NRF1,
nuclear respiratory factor 1; OPA1, optic atrophy type 1; PECAM 1, platelet endothelial cell adhesion
molecule 1; TFAM, mitochondrial transcription factor A.
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muscle fiber CSA was reduced significantly by a mean
;46% from 18 to 28 mo of age, suggesting that myofiber
atrophy is the predominant cause of the loss of skeletal
muscle mass that occurs between these ages.
Long-term administration of mitochondria-
targeted antioxidant mitoquinone mesylate
fails to attenuate age-related mtROS increase
in muscle fibers from old mice
Previous studies from our group (16) and others (17)
have shown that isolated skeletal muscle mitochon-
dria exhibit an age-related increase in H2O2, which is
associated with increased mitochondrial oxidative
damage (21). To assesswhether age-dependentmtROS
increase and oxidative damage are contributing fac-
tors to the loss of muscle mass that occurs with aging,
24-mo-old mice were treated with mitochondria-
targeted mitoquinone mesylate for 15 wk. We chose
to administer the compound to animals between the
ages of 24 and 28 mo because our data (Fig. 1A)
revealed that loss of muscle mass occurs after 24 mo of
age. To assess the antioxidant effect of mitoquinone
mesylate, single muscle fibers isolated from the AT
muscle of control and mitoquinone mesylate-treated
old mice were loaded with MitoSOX Red (Fig. 2A,
upper). mitoquinone mesylate treatment was found
to increase the 2-OH-Mito-E+ fluorescence (Fig. 2A,
lower), indicating a potential increase in mitochon-
drial superoxide production. To further assess changes
in mtROS in the presence of mitochondrial substrates
and inhibitors, we determined H2O2 efflux from intact
mitochondria in permeabilizedmyofibers from the AT
muscle (Fig. 2B, C). Saponin-permeabilized fibers from
the AT muscle displayed good morphology and well-
defined striations along the sarcolemma and stained
positive for To-Pro-1 iodide (Thermo Fisher Scientific),
indicating plasma membrane permeabilization (Fig. 2B).
Glutamate/malate (complex I substrates) and succinate
(complex II substrate) fueled mitochondria from treated
old mice showed a tendency toward a higher increase in
H2O2 emission compared to control oldmice (Fig. 2C) but
did not reach statistical significance. The succinate in-
duced H2O2 release was abolished by the complex I in-
hibitor rotenone, suggesting that this H2O2 release likely
derives from complex I (Fig. 2C).
Because these results were unexpected, we next
sought to determine whether long-term administra-
tion of mitoquinone mesylate altered the expression
of potential sources for mtROS generation, including
complexes I, II, and III (41) and mitochondrial nico-
tinamide adenine dinucleotide phosphate oxidase 4
(NOX4) (14, 36). To assess mitochondrial protein lev-
els of NOX4, mitochondrial and cytosolic fractions
from skeletal muscle of control and mitoquinone
mesylate-treated old mice were prepared (Fig. 2E).
We observed no changes in protein expression of
complexes I, II, and III (Fig. 2D) or mtNOX4 (Fig. 2F).
Similarly, no changes were observed in the enzymatic
activities of respiratory complex I (Fig. 2G) or mito-
chondrial matrix superoxide dismutase (SOD) 2 (Fig.
2H). A tendency to a reduction in SOD1 activity was
observed in skeletal muscle of mitoquinone mesylate-
treated old mice compared to control old mice (P =
0.06). These findings were somewhat surprising but
indicate that long-term mitoquinone mesylate treat-
ment of old mice failed to attenuate the age-related
increase in ROS generation by intact mitochondria in
isolated skeletal muscle fibers.
Mitoquinone mesylate fails to attenuate
oxidative damage in aging skeletal muscle
Todeterminewhether long-termmitoquinonemesylate
treatment altered levels of age-related oxidative
damage in skeletal muscle (42–44), we next examined
the amounts of protein oxidation, lipid peroxidation,
DNA damage, and protein nitration (Fig. 3). Mito-
quinone mesylate treatment tended to increase age-
related protein carbonylation (9) in whole AT muscle
(Fig. 3A, upper left) and mitochondrial fractions (Fig.
3A, upper right). There was also a tendency for an
Figure 1. Sarcopenia is associated with myoﬁber
atrophy. A) Age-related changes in AT muscle
mass, normalized to BW. *P , 0.05 compared
to values from other age groups (n = 6–8 mice
per group). B) Transverse section of AT muscle
from 18-mo-old mouse stained with WGA (5
mg/ml, red), to visualize extracellular matrix
and to assess total ﬁber numbers and CSA of
individual ﬁbers. Scale bar, 500 mm. C)
Number of muscle ﬁbers in AT muscle from
18- and 28-mo-old mice. D) Average ﬁber CSA
of individual ﬁbers from AT muscle of 18- and
28-mo-old mice. *P , 0.05 compared to values
from 18-mo-old mice (n = 6–8 mice per group).
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increase in protein carbonyl content of cytosolic frac-
tions from mitoquinone mesylate-treated mice (Fig.
3A, lower). Assessment of lipid peroxidation in mito-
chondrial and cytosolic fractions from skeletal muscle
of control and mitoquinone mesylate-treated old mice
was undertaken by immunoblotting for 4-hydrox-
ynonenal (4-HNE) protein adducts (Fig. 3B). The data
obtained were similar to those for protein oxidation in
that mitoquinone mesylate treatment tended to in-
crease lipid peroxidation in both fractions (Fig. 3B).
However, neither protein carbonylation nor lipid
peroxidation markers showed statistically significant
differences between control and mitoquinone mesylate-
treated mice. The extent of oxidative DNA damage was
also assessed by examining 8-OHdG in genomic DNA
and protein expression of oxoguanine DNA glycosylase
(OGG1), a primary enzyme responsible for the excision
of 7,8-dihydro-8-oxoguanine lesion (45) (Fig. 3C). Muscle
from mitoquinone mesylate-treated old mice showed a
trend toward a reduction (P = 0.09) in OGG1 protein
levels (Fig. 3C, right and lower), with no change in the
levels of 8-OHdG (Fig. 3C, left). Finally, the level of
protein nitration (3-nitrotyrosine, 3-NT) and the ex-
pression of peroxiredoxin V (PRXV), a peroxynitrite
reductase (7), were determined (Fig. 3D), but no effects
on 3-NT content (Fig. 3D, left) or PRXV expression (Fig.
3D, right and lower) were observed. Overall, these data
indicate that long-term administration of mitoquinone
mesylate did not reduce oxidative damage in muscle of
old mice.
Figure 2. Effect of long-term mitoquinone mesylate (MitoQ) administration on mtROS in skeletal muscle of old mice. A) Upper
panels: representative images of single ﬁber isolated from AT muscle under bright-ﬁeld ﬂuorescent image after loading with
MitoSOX Red (20 nM, cyan) and merged image as indicated and analyzed by confocal microscopy. Original magniﬁcation, 360.
Scale bar, 25 mm. Lower panel: statistical analysis of area under mitochondrial 2-OH-Mito-E+ ﬂuorescence trace (area under
curve) over 60 min for control old mice and mice treated with MitoQ for 15 wk (24–28 mo old), arbitrary units (AU). 2-OH-Mito-E+
ﬂuorescence was normalized to CS activity. *P , 0.05 compared to values from MitoQ-treated old mice (n = 12 ﬁbers, 5–6 mice
per group). B) Confocal images of saponin-permeabilized ﬁber isolated from AT muscle under bright-ﬁeld ﬂuorescent image
after loading with To-Pro-1 iodide (200 nM, green) and DAPI (1 mg/ml, blue); merged image as indicated and analyzed by
ﬂuorescence microscopy. Original magniﬁcation, 360. Scale bar, 25 mm. C) Mitochondrial H2O2 production (normalized per
CS activity) assessed in permeabilized ﬁber bundles prepared from AT muscle of control and MitoQ-treated old mice.
Mitochondrial substrates and inhibitors—glutamate and malate (G/M; 5 mM for both), succinate (S; 10 mM), and rotenone
(Rot; 1 mM)—were added as indicated (n = 5–6 mice per group). D) Protein levels of oxidative phosphorylation (oxphos)
complexes (I, II, III, and V) from AT muscle of control and MitoQ-treated old mice. Intensity of bands shown in Ponceau
S–stained gel (upper) was equivalent to GAPDH and vinculin protein levels (lower) and were used as loading controls. E)
Representative Western blot of GAPDH and voltage-dependent anion channel 3 (VDAC3) content to illustrate purity of extracted
mitochondrial (Mito) and cytosolic (Cyto) skeletal muscle fractions. F) Protein levels of NOX4 in skeletal muscle mitochondrial
fractions of control and MitoQ-treated old mice. G) Rotenone-sensitive respiratory chain complex I activity in AT skeletal muscle
homogenates of control and MitoQ-treated old mice (n = 5–6 mice per group). H) Native gels stained for SOD1 and SOD2
enzyme activities in AT skeletal muscle of control and MitoQ-treated old mice (upper) and densitometric quantiﬁcation of bands
(lower). Negative control (NC) included AT muscle lysate from Sod1-null mice.
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Mitoquinone mesylate alters expression of
redox regulatory proteins in aging
skeletal muscle
To determine whether long-term mitoquinone mesylate
treatment of old mice caused adaptations in the expression
of proteins involved in antioxidant defense, we measured
the expression of redox regulatory proteins, including
SOD isoforms (Fig. 4A); NOS isoenzymes (Fig. 4B); H2O2-
scavenging enzymes, including glutathione peroxidase 1,
catalase, and PRXIII (Fig. 4C); redox proteins involved in
the thioredoxin–peroxiredoxin (TRX-PRX) system(Fig. 4D);
and heat shock proteins (Fig. 4E), which have all been
showntoprovideprotectionagainst thedamagingeffects of
increased reactive oxygen and nitrogen species (RONS)
production (6, 9). Densitometric quantification (Fig. 4F) of
the blots presented in Fig. 4A–E revealed a significant re-
duction in protein expression of extracellular SOD3 isoform
and mitochondrial SOD1. This was also associated with a
trend toward increased levels of TRX-PRX regulatory pro-
teins including thioredoxin reductase 1 (TRXR1), mito-
chondrial TRXR2, and iNOSanda reduction inHSC70 (Fig.
4F). TheNF-kB signaling pathway is known to regulate the
expression of iNOS (46) and ROS antioxidant enzymes (4),
and previous in vitro studies have demonstrated enhanced
NF-kB activation after incubation with mitoquinone mesy-
late (47). We therefore examined activation of the NF-kB
pathway,whichwepreviouslydemonstratedtobe increased
in skeletal muscle of old mice (48). Muscle of mitoquinone
mesylate-treated old mice showed no significant change in
activation of the NF-kB pathway as indicated by phosphor-
ylationof IkB-a, total IkB-a content (akey inhibitor ofNF-kB
activation), or NF-kB-P65 protein content (total and phos-
phorylated) (Fig. 4G). Overall, these data suggest that long-
term treatment of mitoquinone mesylate may have altered
the expressionof a small numberof specific redox regulatory
proteins in skeletal muscle from old mice.
Long-term mitoquinone mesylate treatment
does not affect mitochondrial abundance in
skeletal muscle of old mice
We sought to determine whether mitoquinone
mesylate-treated old mice showed a change in mito-
chondrial abundance (15, 20) (Fig. 5A, B). Muscle of
treated old mice showed a tendency to a reduction in
mtDNA copy numbers per nuclear genome (Fig. 5A)
and CS activity (Fig. 5B). Real-time qRT-PCR analysis
of expression of genes involved in mitochondrial
dynamics (fusion and fission) and biogenesis (Fig. 5C,
upper) showed that mRNA levels were similar be-
tween muscle of mitoquinone mesylate-treated and
control old mice (Fig. 5C, lower). Protein levels of
Figure 3. Markers of oxidative damage in skeletal muscle from mitoquinone mesylate (MitoQ)-treated old mice. A) Western blot
analysis and quantiﬁcation (lower right) of protein carbonyls in mitochondrial (upper right) and cytosolic (lower left) skeletal
muscle fractions, and AT lysates (upper left) of control and MitoQ-treated old mice. B) Western blot analysis (left) and
quantiﬁcation (right) of 4-HNE protein adducts in mitochondrial (upper left) and cytosolic skeletal muscle fractions (lower left)
of control and MitoQ-treated old mice. C) Levels of 8-OHdG in genomic DNA extracted from skeletal muscle (upper left), and
OGG1 protein levels (lower) of skeletal muscle from control and MitoQ-treated old mice and densitometric quantiﬁcation of blot
(n = 5–6 mice per group; upper right). D) 3-NT content (upper left) and PRXV protein levels (lower) of skeletal muscle from
control and MitoQ-treated old mice and densitometric quantiﬁcation of blot (n = 5–6 mice per group; upper right).
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the transcriptional coactivator and regulator of
mitochondrial biogenesis peroxisome proliferator-
activated receptor a (PGC-1a) did not differ between
control and mitoquinone mesylate-treated old mice
(Fig. 5D). A potential effect on mitophagy was in-
vestigated using isolated mitochondrial fractions from
skeletal muscle of control and mitoquinone mesylate-
treated old mice immunoblotted for PTEN-induced pu-
tative kinase 1 (PINK1), and ubiquitin ligase Parkin
mitophagy markers (Fig. 5E). We observed increased re-
cruitment of PINK1 but no significant difference in Parkin
in isolated mitochondria from mitoquinone mesylate-
treatedoldmice (Fig. 5E) compared tovalues fromcontrol
old mice, suggesting an increased mitophagic response.
Levels of sirtuin 1 (Fig. 5D), an important regulator of mi-
tochondrial recycling through the process of autophagy
(49), were unchanged in the treated mice.
Long-term mitoquinone mesylate treatment
does not influence mitochondrial membrane
potential in intact mitochondria of
permeabilized muscle fibers in old mice
Cumulative oxidative damage has been proposed to
induce age-associated reductions in mitochondrial
function (24, 50). We thus we investigated mitochon-
drial function in skeletal muscle of mitoquinone
mesylate-treated old mice (Fig. 6). Skeletal muscle
of mitoquinone mesylate-treated old mice exhibited
similar levels of mitochondrial aconitase activity
(Fig. 6A) and mitochondrial protein levels (Fig. 6B,
upper right) compared to control old mice, although
a tendency to a reduction in aconitase content (P =
0.06) was observed in the cytosolic compartment
of the AT muscle (Fig. 6B, lower left). The DCm of in-
tact mitochondria in isolated AT muscle fibers was
examined by changes in TMRM fluorescence (Fig. 6C,
upper) after treatment with oligomycin and the pro-
tonophore FCCP (Fig. 6C, center). Statistical analysis
of the area under the TMRM fluorescence trace
revealed differences between mitoquinone mesylate-
treated and control old mice (Fig. 6C, lower). Next,
we evaluated mitochondrial respiratory function in
saponin-permeabilized fiber bundles after addition
of glutamate/malate substrates and ADP. Myofibers
from mitoquinone mesylate-administered old mice
showed a trend toward a reduction (P = 0.17) in
RCI (Fig. 6D, left) associated with a trend toward
increased uncoupling protein (UCP) 2 protein levels
(P = 0.06) (Fig. 6E). No changes in P:O ratio (Fig. 6D,
Figure 4. Effect of long-term mitoquinone mesylate (MitoQ) treatment on RONS regulatory protein expression in skeletal muscle of
old mice. A) Representative Western blots depicting SOD isoform expression in AT lysates and mitochondrial/cytosolic skeletal muscle
fractions of control and MitoQ-treated old mice. B) Protein expression levels of NOS isoforms in AT lysates of control and MitoQ-
treated old mice. C) Western blots of main H2O2-reducing enzymes, including catalase (CAT), glutathione peroxidase 1 (GPX1), and
PRXIII, in AT lysates of control and MitoQ-treated old mice. D) Protein expression of main redox proteins involved in TRX-PRX
system, including TRX1, TRX2, TRXR1, and TRXR2, in AT lysates of control and MitoQ-treated old mice. E) Western blots of heat
shock proteins in AT lysates of control and MitoQ-treated old mice. F) Densitometric analysis of represented Western blots shown in
A–E. *P, 0.05 compared to values from old control mice. G) Effect of long-term MitoQ treatment on total and phosphorylated IkB-a
(phospho IkB-a) and P65 content (total and phosphorylated) (lower left), and densitometric quantiﬁcation of blots (right).
Coomassie Brilliant Blue–stained gel (upper left) served as loading control. M, molecular weight marker.
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right) or UCP3 protein expression (Fig. 6E) were observed
in mitoquinone mesylate-treated old mice compared to
control old mice.
Mitochondrial-mediated apoptosis is not
altered in response to long-term mitoquinone
mesylate treatment in aging skeletal muscle
A variety of proapoptotic markers were examined, in-
cluding expression of BAK, BAX, and VDAC1 (Fig. 7A),
proteolytic enzymes linked to apoptosis including expres-
sion of calpain I and calpastatin (Fig. 7B), mitochondrial
release of cytochrome c and Smac/DIABLO proapoptotic
proteins to cytosol (Fig. 7C), mitochondrial endonucleaseG
(Fig. 7D), and DNA fragmentation of genomic DNA (Fig.
7E). These results showed no changes in mitochondrial-
mediated apoptotic processes in response to mitoquinone
mesylate treatment.
Long-term administration of mitoquinone
mesylate failed to prevent loss of muscle
mass and function that occurred with aging
We examined whether long-term mitoquinone mesy-
late treatment affected muscle mass and structure in
oldmice. The trend lines depicted in Fig. 8A showed no
changes in BW during the 15-wk treatment. The tissue
weights of several skeletal muscles and organs did not
differ significantly between control and mitoquinone
mesylate-treated old mice (Table 2), although there
was a trend toward reduced spleenmass (P = 0.12) and
increased kidney mass (P = 0.1). To assess changes in
muscle morphology, transverse sections of AT muscle
from control and mitoquinone mesylate-treated old
mice were double immunolabeled with WGA (to vi-
sualize extracellularmatrix) andDAPI (tomark nuclei)
(Fig. 8B). Histologic analysis revealed no changes in
number of centrally nucleated fibers (Fig. 8C, left),
total number of fibers per ATmuscle (Fig. 8C, right), or
average muscle CSA (Fig. 8C, lower) in response to the
mitoquinone mesylate treatment. Quantitative analy-
sis of individual fiber CSA showed no differences in
myofiber size (Fig. 8D) or fiber type distribution (Fig.
8E) of AT or gastrocnemius skeletal muscles between
control and mitoquinone mesylate-treated old mice.
Next, we examined the effect of mitoquinone mesylate
administration on age-related changes in muscle
function (5, 17) (Fig. 8F–J). Functional measurements
of EDL muscle force production in situ revealed no
changes in maximum isometric specific force between
Figure 5. Effect of long-term mitoquinone mesylate (MitoQ) administration on mitochondrial content and mitophagy in skeletal
muscle of old mice. A) Real-time qRT-PCR measurement of mtDNA, normalized to amount of nuclear DNA (nDNA) in skeletal
muscle of control and MitoQ-treated old mice (n = 5–6 mice per group). B) CS activity in skeletal muscle of control and MitoQ-
treated old mice (n = 5–6 mice per group). C) Representative image of agarose gel electrophoresis of real-time RT-PCR
ampliﬁcation products of GAPDH, B2M, RPS29, COXI, COXIV, CS, MCIP1, mitochondrial transcription factor A (TFAM), PGC-
1a, nuclear respiratory factor 1 (NRF1), OPA1, MNF1, MNF2, FIS1, and DRP1 transcripts (upper). Lanes 1 and 17, 100 bp DNA
molecular weight marker. PCR products correspond to amplicon sizes listed in Table 1. Relative mRNA levels of genes involved in
mitochondrial biogenesis and dynamics analyzed by real-time qRT-PCR (lower). mRNA levels were normalized against the
housekeeping genes GAPDH, B2M, and RPS29. D) Protein expression of sirtuin 1 (Sirt1) and PGC-1a mitochondrial biogenesis
regulators (left) in AT skeletal muscle of control and MitoQ-treated old mice and densitometric quantiﬁcation of blots (right). E)
Western blots of isolated mitochondrial fractions from skeletal muscle of control and MitoQ-treated old mice immunodetected
for PINK1, and ubiquitin ligase Parkin, mitophagy markers (left), and densitometric quantiﬁcation of blots (right).
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control and mitoquinone mesylate-treated old mice (Fig.
8F). In situ measurements of the decline in force genera-
tion by EDLmuscles during a series of repeated isometric
contractions revealed a trend toward a greater decline in
force in mitoquinone mesylate-treated mice compared to
values from control old mice, but the apparent greater
decline in the mitoquinone mesylate-treated mice was
not statistically different (Fig. 8G). Finally, to evaluate the
force production at the single-fiber level, we recorded ex
vivomuscle force of single isolated skinned fibers (Fig. 8H)
obtained from theATmuscle. This allowed us to examine
the forcegeneratedbysarcomericproteins independentof
innervation, fiber number, ATP levels, and calcium
release (51). Neither specific force (Fig. 8I) nor the
time to peak maximum tension (Fig. 8J) differed be-
tween the control and mitoquinone mesylate-treated
old mice. Collectively, these data reveal that long-
term mitoquinone mesylate treatment did not alter
age-related muscle atrophy, or any of functional
deficits associated with aging skeletal muscle.
DISCUSSION
Considerable evidence has indicated that skeletal
muscle decline with advancing age is associated with
an increased oxidative status in redox-responsive
proteins (52) and increased oxidative modifications
Figure 6. Mitochondrial function in skeletal muscle of mitoquinone mesylate (MitoQ)-treated old mice. A) Mitochondrial
aconitase (ACONS) activity in AT skeletal muscle of 28-mo-old control and MitoQ-treated mice (n = 5–6 mice per group). B)
Western blot analysis and quantiﬁcation (lower right) of ACONS in mitochondrial (upper right) and cytosolic (lower left)
skeletal muscle fractions, and AT lysates (upper left) of control and MitoQ-treated old mice. C) Confocal images of single ﬁber
isolated from AT muscle under bright-ﬁeld ﬂuorescent image after loading with TMRM ﬂuorescence (20 nM, red); merged
image as indicated and analyzed by ﬂuorescence microscopy. Original magniﬁcation, 360. Scale bar, 30 mm (upper);
Measurement of DCm in intact mitochondria of isolated AT ﬁbers from control and MitoQ-treated old mice, assessed by changes
in TMRM ﬂuorescence in response to oligomycin (Olm; 2.5 mM) and FCCP (4 mM), added at indicated time points (center);
statistical analysis of area under TMRM ﬂuorescence trace (area under curve) for control and MitoQ-treated old mice (n = 10–12
ﬁbers, 5–6 mice per group; lower). D) Respiratory function of intact mitochondria in saponin-permeabilized myoﬁbers from
control and MitoQ-treated old mice shown by changes in RCI (left) and ratio of ATP amount to consumed O2 during state 3 (P:O
ratio) (right) (n = 5–6 mice per group). E) UCP2 and UCP3 protein levels in skeletal muscle of control and MitoQ-treated old
mice (left) and densitometric quantiﬁcation of blots (right).
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of macromolecules including DNA, proteins, and lipids
(4). Altered mitochondrial redox homeostasis has been
proposed to play a key role in sarcopenia (19, 21, 53), and
skeletal muscle mitochondria have been reported to ex-
hibit an age-dependent increase inmtROS (16, 17). Aging
of skeletal muscle is associated with mitochondrial dys-
function including reduced maximal ATP-generating
capacity, impaired function of the mitochondrial per-
meability transition pore, and reduced maximal respira-
tory capacity (21, 31). Although cumulative oxidative
damage has been suggested to induce age-associated
decline in mitochondrial function (24), the effect of mi-
tochondrial dysfunction and mtROS as the underlying
key regulators of the age-related atrophy process re-
mains an area of active research (25, 26).
Skeletal muscle produces ROS from a variety of sub-
cellular sites (14), and studies assessing the potential role of
mtROS as the underlying mechanism of mitochondrial
dysfunction and muscle wasting have been restricted in
part by a the lack of interventions to selectively target
mtROS. In the current study, we determined the time
course of age-related phenotypic/structural changes that
occur in skeletal muscle and assessed the contribution of
mtROS by utilizing the mitochondria-targeted ubiquinone
derivative mitoquinone mesylate, which may selectively
protect mitochondria from oxidative damage.
Data indicate that age-related loss of muscle mass
occurred after 24mo of age in these C57BL/6mice and
was attributed to a significant reduction in fiber CSA
compared to 18-mo-old mice. Our findings are in
agreement with recent human studies, highlighting
age-dependent fiber atrophy as a primary cause of loss
of muscle mass with advancing age (22).
Previous work from our group (16) and others (17)
has shown that age-dependent loss of muscle mass
and function is associated with increased mitochon-
drial H2O2 emission and oxidative damage (21),
suggesting that changes in mitochondrial redox ho-
meostasis toward an oxidized state may be a contribu-
tor to skeletal muscle aging. To directly assess the effect
of age-related changes in the mitochondrial redox en-
vironment, we used a long-term drug intervention
approach with use of mitoquinone mesylate. This
compound has been developed as a therapy for hu-
mans and has undergone phase 1 and 2 clinical trials
(28); it comprises a ubiquinone moiety covalently at-
tached through an aliphatic 10-carbon chain to triphe-
nylphosphonium, a lipophilic cation that accumulates
several hundred–fold within mitochondria (54, 55).
Mitoquinone mesylate is absorbed/bound to the
matrix-facing surface of the inner mitochondrial mem-
brane (into the hydrophobic core of the phospholipid
bilayer) (54), driven by the membrane potential, and
there it is thought to be continually recycled to the active
ubiquinol antioxidant by complex II of the respiratory
chain (28).
Figure 7. Effect of long-term mitoquinone mesylate (MitoQ) treatment on mitochondrial-mediated apoptosis in skeletal muscle.
A) Immunoblots of BAK, BAX, and VDAC1 proapoptotic proteins in skeletal muscle of control and MitoQ-treated old mice (left)
and densitometric quantiﬁcation of blots (right). B) Protein expression levels of calpain I and calpastatin proteolytic enzymes in
muscle of control and MitoQ-treated old mice (left) and densitometric quantiﬁcation of blots (right). C) Western blots of
isolated cytosolic fractions of control and MitoQ-treated mice immunodetected for cytochrome c (Cyt C) and Smac/DIABLO
mitochondrial proapoptotic proteins (left), and densitometric quantiﬁcation of blots (right). D) Protein levels of proapoptotic
factor endonuclease G (Endo G) in skeletal muscle mitochondrial fractions of control and MitoQ-treated old mice (left) and
densitometric quantiﬁcation of blot (right). E) DNA fragmentation of genomic DNA isolated from skeletal muscle of control and
MitoQ-treated old mice analyzed by agarose-gel electrophoresis. Lanes 1 and 10, 1 kb DNA molecular weight marker.
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Figure 8. Effect of long-term mitoquinone mesylate (MitoQ) treatment on age-related loss of muscle mass and function. A) Time
course of changes in mouse BW during 15 wk of mito-targeted MitoQ administration. Trend lines indicate no changes in BW during
treatment period; BW was monitored weekly (n = 5–6 mice per group). B) Transverse sections of AT muscle from 28-mo-old control
and MitoQ-treated mice obtained after 15-wk treatment period, and stained with WGA (5 mg/ml, green) to visualize extracellular
matrix and DAPI (1 mg/ml, blue) to mark nuclei. Scale bar, 400 mm. C) Percentage of ﬁbers showing centrally located nuclei in AT
muscle of control and MitoQ-treated old mice (upper left); total number of muscle ﬁbers in AT muscle of control and MitoQ-
treated old mice (upper right); mean CSA of individual ﬁbers from AT muscle of control and MitoQ-treated old mice (n = 5–6 mice
per group; lower). D) Frequency distribution of ﬁber CSA of AT muscle from control and MitoQ-treated old mice (n = 5–6 mice per
group). E) Representative Western blots of fast [myosin heavy chain (MHC) fast] and slow (MHC slow) MHC content in
gastrocnemius (GTN, upper) and AT muscle (lower) of control and MitoQ-treated old mice. F) Maximum isometric speciﬁc force
measured in situ, normalized to total ﬁber CSA of EDL muscle from control and MitoQ-treated old mice (n = 5–6 mice per group).
G) In situ measurements of drop in maximum isometric speciﬁc force of EDL muscle during series of repeated isometric
contractions (300 ms at 100 Hz every 5 s), expressed as percentage of initial force. Lines represent average response of 5 muscles
(n = 5 mice per group). Although MitoQ-treated old mice showed tendency to greater decline in isometric force production during
fatiguing protocol compared to controls, data were are not statistically signiﬁcantly. H) Image of skinned myoﬁber isolated from AT
muscle of 28-mo-old mouse attached to force transducer and high-speed length controller. Scale bar, 350 mm. I) Ex vivo
measurements of maximum ﬁber speciﬁc force normalized to ﬁber CSA of skinned myoﬁbers isolated from AT muscle of control
and MitoQ-treated old mice (n = 25 ﬁbers, 5 mice per group). J) Ex vivomeasurements of time to peak maximum tension of skinned
ﬁbers isolated from AT muscle of control and MitoQ-treated old mice (n = 25 ﬁbers, 5 mice per group).
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We assessed the potential of mitoquinone mesylate to
rescuemyofiberatrophyobserved inmicebetween24and28
moof age andprovide evidence that drug treatment failed to
prevent the age-related reduction in fiber CSA. We then ex-
aminedtheeffectof long-termadministrationofmitoquinone
mesylate toattenuateage-dependentchanges inmtROSand
redox homeostasis. To our surprise, mitoquinone mesylate
treatment did not reduce mtROS or provide clear antioxi-
dant protective effects; indeed, we observed an increase in
MitoSOX Red oxidation in the treated mice. Recent in vitro
studies using skeletal muscle C2C12 cells have also pro-
vided similar results; palmitate-induced ROS production
was further increased in response to mitoquinone mesylate
treatment (56). Thus, the lack of any substantial antioxidant
effects in response to mitoquinone mesylate administration
did not allow us to directly address the original question
posed in the current study:whether age-dependent changes
inmitochondrial redoxhomeostasisplayamajor role inage-
related muscle atrophy.
Skeletalmuscleofmitoquinonemesylate-treatedoldmice
showedsomealterations in the expression levels andactivity
of RONS regulatory systems and elevated mitophagic po-
tential.Wefurtheraddressedwhethermitoquinonemesylate
influenced age-related changes in mitochondrial function
andmuscle force.We found that long-termadministration
of mitoquinone mesylate did not significantly alter mito-
chondrial function ormuscle function, although therewas
a tendency to adversely affect mitochondrial respiration
and a decline in force during a series of repeated isometric
contractions. It is noteworthy that neither of these
analyses reached statistical significance. In relation to
this, recent in vitro studies using state-of-the-art respi-
rometer technology (Seahorse Bioscience, North Billerica,
MA, USA) have reported decreased mitochondrial res-
piration (56) and respiratory uncoupling (57) in skeletal
muscleC2C12myoblasts and endothelial cells in response
to mitochondria-targeted coenzyme Q analogs.
The relative increase in MitoSOX Red oxidation indi-
cating increased mtROS observed in response to long-
term administration of mitoquinone mesylate in vivomay
be related to the quinone group, which has previously
been shown to participate in redox cycling (53, 58).
Quinone-containingcompoundsmayundergoa1-electron
reduction by flavin-containing enzymes to form semi-
quinone radicals,which in turnmay rapidly reactwithO2
to produce superoxide (59, 60). The work presented in
this study indicates that mitochondrial superoxide pro-
duction, assessed via changes in MitoSOX Red fluores-
cence, was increased in response to the drug treatment.
Other in situ and in vitro studies have also provided evi-
dence that mitoquinone mesylate can augment mtROS
production by complex I (58, 61), and previous work us-
ing submitochondrial particles and purified mitochon-
drial complex I also suggested that redox cycling of
mitoquinonemesylate canoccurat the 2 siteson complex I
proximal and distal to the rotenone binding site (53).
Potential prooxidant effects ofmitoquinonemesylate in
vivomay also potentially be explained by the localization
of its large hydrophilic core in the aqueous phase. Factors
that favor superoxide production by ubiquinones are re-
duction to the ubiquinol and the extent to which they are
present in the aqueous environment (28, 62). Deprotona-
tion of ubiquinol, the reduced form of mitoquinone
mesylate, in the aqueous phase could lead to an oxidation
reaction of quinol, generating superoxide (53, 62). These
potential mechanisms offer plausible explanations why
the current study has indicated that long-term mitoqui-
none mesylate treatment enhanced mtROS production in
skeletal muscle of old mice.
Previous in vivo studies have subjected rodents to long-
termadministrationofmitoquinonemesylate inwild-type
C57BL/6 (28) as well as a transgenic mouse model of
Alzheimer disease (27) and have showed either antioxi-
dant protective effects (27) or lack of changes in redox
homeostasis (28) in brain, liver, and heart tissue. Both of
these studies used young mice (4–8 wk old), and the re-
sponses of tissues to this compound may potentially
change in old organisms. Alternatively, it is possible that
the inherent differences in specific tissue redox potential
may alter the efficacy of mitoquinone mesylate in pro-
tecting mitochondria from oxidative damage.
To our knowledge, this is the first study to utilize a long-
term mitoquinone mesylate pharmacologic approach and
to examine the effect on skeletal muscle mitochondrial re-
doxhomeostasis, organelle integrity,andfunctionaswell as
age-related loss of muscle mass and function. Mitoquinone
mesylate failed to attenuate age-related oxidative damage
or rescue the sarcopenic phenotype and functional deficits
associated with aging of skeletal muscle.
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TABLE 2. Comparison of tissue weights from control and mitoquinone
mesylate-treated old mice
Tissue MitoQ Control
BW (g) 35.2 6 1.4 33.6 6 2.6
AT (mg) 43.4 6 3.4 40.4 6 2.9
EDL (mg) 10.1 6 0.5 9.8 6 0.3
Gastrocnemius (mg) 154.6 6 9.9 139.3 6 6.6
Soleus (mg) 9.8 6 0.7 8.7 6 0.4
Liver (g) 1.91 6 0.16 1.8 6 0.13
Spleen (mg) 134 6 21.1 273.3 6 72.3
Kidney (mg) 273.2 6 25.9 226.1 6 12.8
Heart (mg) 211.4 6 14 195.3 6 14.5
Lung (mg) 185.2 6 2.5 175.3 6 8.9
Brain (mg) 488.8 6 4.9 468.6 6 8.9
MitoQ, mitoquinone mesylate. Values are presented as means 6
SEM (n = 5–6 mice per group).
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